drug

ziprazidone

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Centre for Addiction and Mental Health
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
NCT00818298—Completed
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00159757Phase 4Terminated

KOLs & investigators

1
David C. Mamo, MD, MSc

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Centre for Addiction and Mental Health
company
trial
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
NA
trial
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
PHASE4
trial
indication
Schizophrenia
indication
Patient Compliance
indication
Schizophrenia
indication
Dissociative Disorders
indication
KOL
David C. Mamo, MD, MSc
KOL score —
person